Stock News

Texan Capital Management Has Lowered Its Hff (HF) Position; Alnylam Pharmaceuticals (ALNY) Sentiment Is 2.03

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Texan Capital Management decreased Hff Inc. (HF) stake by 40.34% reported in 2017Q4 SEC filing. Texan Capital Management sold 30,135 shares as Hff Inc. (HF)’s stock rose 9.49%. The Texan Capital Management holds 44,572 shares with $2.17 million value, down from 74,707 last quarter. Hff Inc. now has $1.37 billion valuation. The stock decreased 0.53% or $0.185 during the last trading session, reaching $34.965. About 62,599 shares traded. HFF, Inc. (NYSE:HF) has risen 93.80% since May 24, 2017 and is uptrending. It has outperformed by 82.25% the S&P500.

Alnylam Pharmaceuticals Inc (ALNY) investors sentiment increased to 2.03 in 2017 Q4. It’s up 1.11, from 0.92 in 2017Q3. The ratio is more positive, as 150 funds increased or opened new positions, while 74 sold and trimmed stock positions in Alnylam Pharmaceuticals Inc. The funds in our database now hold: 90.18 million shares, up from 86.02 million shares in 2017Q3. Also, the number of funds holding Alnylam Pharmaceuticals Inc in top ten positions increased from 8 to 9 for an increase of 1. Sold All: 27 Reduced: 47 Increased: 83 New Position: 67.

Investors sentiment increased to 1.97 in 2017 Q4. Its up 0.34, from 1.63 in 2017Q3. It improved, as 11 investors sold HF shares while 47 reduced holdings. 44 funds opened positions while 70 raised stakes. 35.16 million shares or 4.08% more from 33.78 million shares in 2017Q3 were reported. Susquehanna International Grp Llp has invested 0% of its portfolio in HFF, Inc. (NYSE:HF). Cwm Ltd Liability Corp reported 0% in HFF, Inc. (NYSE:HF). Bank Of America De holds 64,631 shares. U S Investors, a Texas-based fund reported 54,600 shares. Stone Ridge Asset Limited Liability, a New York-based fund reported 16,191 shares. Barclays Public Ltd Co holds 0% or 11,517 shares. Dimensional Fund Advsr Lp reported 0.03% of its portfolio in HFF, Inc. (NYSE:HF). Royal Natl Bank Of Canada has invested 0% in HFF, Inc. (NYSE:HF). Northwestern Mutual Wealth Mgmt stated it has 0% of its portfolio in HFF, Inc. (NYSE:HF). Vanguard Group accumulated 3.44M shares. California State Teachers Retirement stated it has 0.01% of its portfolio in HFF, Inc. (NYSE:HF). 4,559 are owned by Hsbc Holdg Pcl. Gam Hldgs Ag stated it has 0.08% in HFF, Inc. (NYSE:HF). Pnc Financial Svcs Inc holds 12,913 shares. Utd Services Automobile Association invested in 38,822 shares or 0.01% of the stock.

Since March 2, 2018, it had 1 insider purchase, and 5 sales for $2.65 million activity. On Monday, March 19 MacKenzie Kevin sold $239,500 worth of HFF, Inc. (NYSE:HF) or 5,000 shares. On Wednesday, May 2 MCANENY DEBORAH H bought $72,140 worth of HFF, Inc. (NYSE:HF) or 2,000 shares. The insider Fowler John sold 25,000 shares worth $1.22M. Lawton Matthew D sold $486,100 worth of HFF, Inc. (NYSE:HF) on Thursday, March 15. The insider Tepedino Michael sold $265,948.

Analysts await HFF, Inc. (NYSE:HF) to report earnings on July, 26. They expect $0.59 earnings per share, up 20.41% or $0.10 from last year’s $0.49 per share. HF’s profit will be $23.07 million for 14.82 P/E if the $0.59 EPS becomes a reality. After $0.33 actual earnings per share reported by HFF, Inc. for the previous quarter, Wall Street now forecasts 78.79% EPS growth.

Among 5 analysts covering HFF Inc (NYSE:HF), 0 have Buy rating, 1 Sell and 4 Hold. Therefore 0 are positive. HFF Inc had 15 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of HFF, Inc. (NYSE:HF) earned “Hold” rating by Wood on Wednesday, April 5. The rating was downgraded by Morgan Stanley to “Equal Weight” on Tuesday, August 4. The firm earned “Market Perform” rating on Wednesday, January 24 by JMP Securities. The stock of HFF, Inc. (NYSE:HF) has “Hold” rating given on Thursday, November 2 by Keefe Bruyette & Woods. Keefe Bruyette & Woods maintained HFF, Inc. (NYSE:HF) rating on Tuesday, October 10. Keefe Bruyette & Woods has “Hold” rating and $37.0 target. Keefe Bruyette & Woods maintained HFF, Inc. (NYSE:HF) rating on Wednesday, June 7. Keefe Bruyette & Woods has “Hold” rating and $3100 target. Keefe Bruyette & Woods maintained it with “Hold” rating and $3700 target in Friday, July 28 report. The firm has “Hold” rating given on Friday, January 19 by Keefe Bruyette & Woods. The rating was downgraded by Goldman Sachs on Wednesday, August 12 to “Neutral”. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, December 21.

Another recent and important HFF, Inc. (NYSE:HF) news was published by Seekingalpha.com which published an article titled: “HFF reports $109.8M sale, $103.6M financing of San Francisco office condo” on May 21, 2018.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” on May 17, 2018, also Seekingalpha.com with their article: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” published on April 25, 2018, Seekingalpha.com published: “Alnylam Pharmaceuticals (ALNY) Q1 2018 Results – Earnings Call Transcript” on May 04, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Wave Life Sciences: What’s Cooking Behind This Innovator?” published on May 23, 2018 as well as Fool.com‘s news article titled: “Alnylam Looks Forward” with publication date: May 08, 2018.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $9.95 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

The stock increased 0.91% or $0.89 during the last trading session, reaching $98.99. About 106,927 shares traded. Alnylam Pharmaceuticals, Inc. (ALNY) has risen 150.73% since May 24, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 EPS, down 27.61% or $0.37 from last year’s $-1.34 per share. After $-1.41 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28% negative EPS growth.

Since January 1, 0001, it had 0 buys, and 10 insider sales for $38.04 million activity.

12 West Capital Management Lp holds 10.75% of its portfolio in Alnylam Pharmaceuticals, Inc. for 700,000 shares. Blue Ridge Capital L.L.C. owns 1.34 million shares or 5.66% of their US portfolio. Moreover, Perceptive Advisors Llc has 5.6% invested in the company for 1.33 million shares. The New York-based Slate Path Capital Lp has invested 5.59% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 43,064 shares.

Ratings analysis reveals 57% of Alnylam Pharma’s analysts are positive. Out of 7 Wall Street analysts rating Alnylam Pharma, 4 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $36.0 while the high is $137.0. The stock’s average target of $87.50 is -11.61% below today’s ($98.99) share price. ALNY was included in 7 notes of analysts from October 6, 2016. The stock has “Neutral” rating by JP Morgan on Thursday, October 6. As per Thursday, October 6, the company rating was maintained by FBR Capital. The firm earned “Mkt Perform” rating on Thursday, October 6 by Leerink Swann. On Thursday, October 6 the stock rating was maintained by Chardan Capital Markets with “Buy”. Needham maintained it with “Buy” rating and $137.0 target in Thursday, October 6 report. The firm has “Hold” rating given on Thursday, October 6 by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, February 2 by Ladenburg Thalmann.

HFF, Inc. (NYSE:HF) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *